ExonHit Announces Successful Completion of the First Phase of EHT Dx14 Ongoing Clinical Validation

31-Mar-2011 - France

ExonHit Therapeutics announced successful completion of the first phase of the validation study of EHT Dx14, a new transcriptomic signature allowing to differentiate, at molecular level, benign breast tumors from malignant ones.

“These very promising first results confirm EHT Dx14 capability to reliably classify breast tumor type in benign and malignant fine-needle aspiration (FNA) samples. Hence, they confirm the initial performances of the test obtained in a previous study. Our goal is now to evaluate EHT Dx14 performances in making the molecular diagnosis of breast tumors in indeterminate FNA samples,” said Loïc Maurel, M.D., President of the Management Board of ExonHit Therapeutics.

“If these good results are confirmed, this new molecular diagnostic test could potentially become, in association with cytopathological analysis, a credible alternative to the systematic use of the more traumatic breast biopsies. It could also contribute to strengthen the role and confirm the interest of cytology use in the diagnostic process of breast tumors. At IGR, we organize once a week a diagnostic day for breast nodules during which we use FNA,” added Philippe Vielh, M.D., Head of the Cytopathological Unit in the Department of Biopathology at the Institut Gustave Roussy in Villejuif (France).

EHT Dx14 was developed using ExonHit’s Genome-Wide SpliceArray™ platform and was licensed from the Institut Gustave Roussy in May 2009. This molecular biology test is intended when assessing a suspicious tumor discovered during mammography to allow the accurate reading of samples obtained by FNA especially in cases where the standard analysis returns an indeterminate result. EHT Dx14 was able during the initial study to differentiate benign breast tumors from malignant ones in 96% of the cases.

EHT Dx14 clinical validation is a two-step process. The first step consisted in confirming the initial performances of the test, as published earlier in Lancet Oncology, in an independent set of malignant and benign FNA samples coming from the Institut Gustave Roussy biobank. In a second step, it will be necessary to demonstrate the added value of the test in the discrimination of indeterminate cytological samples. The first part of the validation which was just completed showed a 91.5% specificity and a 97.9% sensitivity in a panel of 94 cytological samples (47 benign and 47 malignant ones).

On the basis of these excellent results, ExonHit will be starting the second phase of the validation study and the results are expected in July 2011. At the end of this second step, ExonHit plans to offer EHT Dx14, as an Investigational Use Only product, to major cancer centers in France, in the second half of 2011.

https://www.analytica-world.com/en/news/131642/exonhit-announces-successful-completion-of-the-first-phase-of-eht-dx14-ongoing-clinical-validation.html